Semaglutide employment study ties Wegovy to longer work hours in Denmark

A new semaglutide employment study from economists at NYU Abu Dhabi links the drug to more paid work in Denmark, but the gain takes a different form for Ozempic and Wegovy users. Using national registry records from 2018 to 2024, the team reports that people starting subsidised Ozempic for type 2 diabetes became more likely to hold a job, while employed people paying for Wegovy themselves worked more hours. The work is an observational economics paper, not a clinical trial, and it does not change the approved status of semaglutide anywhere.

What the Danish registry data measured

The paper, The Labor Market Effects of GLP-1s, is by Christian Aleman, Veda Narasimhan, Raül Santaeulàlia-Llopis and Tetyana Surovtseva of NYU Abu Dhabi and Fane Groes of Copenhagen Business School. Khaleej Times reported that it came out as a discussion paper from the Centre for Economic Policy Research, a working paper format rather than a peer reviewed journal article. The authors joined population registers, work histories and the national prescription registry into one quarterly panel. They then followed employment, hours, earnings and hourly wages before and after each person filled a first semaglutide prescription. Both brands contain the same Novo Nordisk peptide, a GLP-1 receptor agonist, so the contrast is really between two patient groups and two ways of paying.

Denmark suits this question because it kept the two uses apart. According to the paper, Ozempic gained general reimbursement from the Danish Medicines Agency on 2 May 2018, while Wegovy users pay the full cost. The semaglutide employment study rests on Danish registry data rather than surveys, which avoids recall errors but not selection. People who start a drug early may already be healthier or more motivated. To limit that bias, the main design compares earlier and later starters among people who all began treatment at some point. For diabetes, the sample is narrowed to people who began semaglutide within six quarters of their first insulin prescription. For weight, it covers people without diabetes who had a recorded overweight or obesity diagnosis, defined as a body mass index of 25 or more.

Ozempic gains came mostly from job entry

In the subsidised diabetes group, the preferred estimate shows that starting semaglutide raised the chance of being employed by 4.1 percentage points and added 19.5 hours of work per quarter. Those averages are measured from the sixth quarter after the first prescription onward, so they describe a lasting shift rather than an early bump. The main diabetes sample averaged about 50.5 years of age and was 42 percent female, which makes it older and less attached to work than the weight group. The authors read the pattern as better health pulling people with weaker job ties back into work. Hourly wages did not move in a statistically clear way, so higher earnings came from working more, not from being paid more per hour.

In the subsidised diabetes group, the preferred estimate shows that starting semaglutide raised the chance of being employed by 4.1 percentage points and added 19.5 hours of work per quarter.

The size of that job effect depends on the comparison. In three robustness checks, the employment gain was 0.8 points when continuing users were set against early dropouts, 2.1 points when semaglutide starters were set against people who began on insulin, and 6.0 points in a matched sample. All three are positive, but the spread is wide. The paper itself warns that the dropout design is more exposed to selection, and persistence is a real issue, since a US claims analysis we covered tied a high starting dose to higher early stopping rates. A separate Danish study by Daysal and colleagues, cited by the authors, found fewer sick days but near zero effects on whether users held jobs. The samples differ, so the job entry question in the GLP-1 labor market literature is not settled.

Wegovy working hours rose but job entry stayed flat

The weight management group looked different from the start. Its main sample averaged 40.5 years of age, was 87 percent female and had a baseline employment rate of 0.73, according to the summary tables in the paper. Among these out of pocket Wegovy users, starting treatment did not clearly raise the chance of having a job. Those who already worked, however, logged 29.7 more hours per quarter, a little over two hours a week, and about 7,589 Danish kroner more in quarterly earnings. Because Wegovy reached Denmark later, follow up is shorter, and these averages start from the fourth quarter after the first prescription rather than the sixth. That shorter window means the hours effect has been tracked for a briefer period than the diabetes result.

Wegovy working hours are the largest single effect in the paper, but the group is narrow. People who can pay the full cost of a weight drug may differ from people who cannot in income, job type and health habits, and comparing earlier with later payers only partly deals with that. The authors note that some alternative designs, including the dropout and matched comparisons, did find a positive effect on job entry for this group as well, and they stress that the hours result held across their specifications. Even so, the findings describe Danish semaglutide injection users between 2018 and 2024. They say nothing direct about tirzepatide or about the Wegovy pill, which came after the study period and which this paper did not study.

Tax revenue claims and open questions

The fiscal part of the paper is where the press framing runs ahead of the numbers. The authors fed their estimates into a simple public finance accounting model. Under 2023 pricing, when annual public subsidies reached 14,130 kroner per patient, they estimate the diabetes track ran a net deficit of 8.00 million kroner per 1,000 users. After the tighter reimbursement rules and price caps of 2024, subsidies fell to 8,695 kroner per patient and the deficit to 2.56 million kroner. In the paper's own words, the diabetes track "does not immediately self-fund" through labor taxes alone. The semaglutide fiscal impact turns positive in their model only when income tax gains from unsubsidised Wegovy users are counted against that public spending.

That result leads the authors to back the Danish choice not to reimburse obesity treatment, an argument built on a stylised model rather than observed budgets. Santaeulàlia-Llopis, as quoted by Khaleej Times, said that judging treatments "purely through clinical metrics like weight loss or blood sugar levels misses the bigger picture." He also asked whether GLP-1 drugs build lasting healthy habits or a new kind of drug dependency. His team plans to test that question in a joint project with the health department of the emirate, which looks at people enrolled in the Thiqa obesity programme. The paper itself leaves lifestyle effects and wider economic shifts to future research. For now, the semaglutide employment study is a careful first estimate from one country with an unusual split between public and private payment.

Conclusion

The semaglutide employment study adds an economic angle to an approved peptide drug without moving it on our board. Its steadiest result is that employed Wegovy users in Denmark worked more hours, while the job entry gain for Ozempic users varies by method. The tax argument depends on a model and on the Danish split between subsidised and private use. Watch for a peer reviewed version, the Thiqa work in Abu Dhabi and similar analyses for other drugs in the incretin pipeline.